NYBA
New York Biotechnology Association
 
 
More...
NYBA: Archived News
NYBA News | Member News | Press Release
 
News type
ZIOPHARM Oncology, Inc.
Headline: ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced
Hematological Malignancies At AACR 2008 Annual Meeting
Date: 16-Apr-2008
News Type: Member News
SAN DIEGO, Apr 16, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented positive data from a phase II study of darinaparsin, the Company's novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, April 12-16, 2008 in San Diego, CA. A total of 40 patient...
Details »
 
OSI Pharmaceuticals Inc.
Headline: OSI Pharmaceuticals Summarizes Data Presented At The Annual Meeting Of The American
Association For Cancer Research
Date: 16-Apr-2008
News Type: Member News
MELVILLE, N.Y.--(BUSINESS WIRE)--April 16, 2008--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided an informational update summarizing highlights from nearly 70 presentations related to the company's oncology portfolio featured at this year's Annual Meeting of the American Association of Cancer Research (AACR) held from April 12th-16th in San Diego, California. &quo...
Details »
 
Pfizer Inc.
Headline: Pfizer And AVANT Enter Into Licensing And Development Agreement For Novel Therapeutic
Vaccine Candidate For Brain Cancer
Date: 16-Apr-2008
News Type: Member News
Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer NEW YORK & NEEDHAM, Mass.--(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today announced that they have entered into an agreement under wh...
Details »
 
Pfizer Inc.
Headline: Results From Largest Statin Study Of Patients With Alzheimer’s Disease Show Lipitor®
Has No Significant Impact On Disease
Date: 16-Apr-2008
News Type: Member News
Results from Largest Statin Study of Patients with Alzheimer’s Disease Show Lipitor® Has No Significant Impact on Disease Study Further Confirms Safety Profile of Lipitor 80 mg In Elderly Patients NEW YORK--(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium...
Details »
 
Pfizer Inc.
Headline: Pfizer Completes Tender Offer For Shares Of Encysive Pharmaceuticals Inc.
Date: 15-Apr-2008
News Type: Member News
NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any requi...
Details »
 
SIGA Technologies, Inc.
Headline: SIGA Advances ST-246 Smallpox Antiviral Development In Europe
Date: 15-Apr-2008
News Type: Member News
NEW YORK, Apr 15, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a 'small and medium-sized enterprise' (SME) with respect to its application for approval of ST-246 in Europe. ST-246 is a sm...
Details »
 
Amgen, Inc.
Headline: Early Data On Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity
Across Tumor Types
Date: 14-Apr-2008
News Type: Member News
AMG 386 Preclinical Data Suggests Greater Reduction in Tumor Growth when Angiopoietin 1/2 and VEGF Pathways are Both Inhibited Abstract Numbers: 1113, 4887 and 5764 SAN DIEGO--(BUSINESS WIRE)--April 13, 2008--Amgen (NASDAQ:AMGN), today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a rec...
Details »
 
Genentech Inc.
Headline: Genentech And Biogen Idec Announce Top-Line Results From A Phase II/III Clinical Trial Of
Rituxan In Primary-Progressive Multiple Sclerosis
Date: 14-Apr-2008
News Type: Member News
Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis South San Francisco, Calif. and Cambridge, Mass. --  April 14, 2008 --  Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) today announced that a Phase II/III study of Rituxan® (rituximab) for primary-progressive m...
Details »
 
Applied DNA Sciences, Inc.
Headline: Applied DNA Sciences Ships Additional Orders For SigNature DNA And DermalRx
Date: 10-Apr-2008
News Type: Member News
STONY BROOK, N.Y., April 09, 2008 /Business Wire/ -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a provider of DNA-based security solutions, today announced that it has shipped follow-on orders of SigNature™ DNA and DermalRx™ in the second fiscal quarter of 2008 which ended March 31, 2008. “We believe these orders are significant steps forward for bo...
Details »
 
Pfizer Inc.
Headline: Pfizer Statement On Exubera Labeling Update In The United States
Date: 10-Apr-2008
News Type: Member News
NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used Exubera. This update is based on an ongoing review of the data from the Exubera clinical trial program and post-marketing expe...
Details »
 
« Previous Next »
   
  © 2007 New York Biotechnology Association HOME | ABOUT NYBA | CONTACT US | SITE MAP Website by Axxiem